glp 1 and parkinson's disease GLP-1 Disease: Research, Benefits and Risks GLP-1 receptor agonists in Parkinson's

Further, targeted metabolomics results revealed that GGCT knockdown markedly attenuated TCA cycle flux, decreasing key intermediates including pyruvate, succinate and fumarate (Fig

To investigate whether NR supplementation affected neurological symptoms for A-T patients, whole blood NAD + concentrations on seven different time points over two years were measured 320

This interplay between iron metabolism and hypoxia is particularly significant in the context of CSCs, which reside in hypoxic niches [91] and leverage these adaptive responses to sustain their stemness properties and resistance to therapeutics (reviewed [92])

PMID: 40005999 [SOURCED]

Obesity paradox in recurrent attacks of gout in observational studies: clarification and remedy